123 / 154
449
Cancer Basic Clin Res 2015;9:19–24.
113. Duchnowska R, Dziadziuszko R, Trojanowski T, et al. Conversion
of epidermal growth factor receptor 2 and hormone receptor
expression in breast cancer metastases to the brain. Breast
Cancer Res 2012;14:R119.
114. Long GV, Menzies AM, Nagrial AM, et al. Prognostic and
clinicopathologic associations of oncogenic BRAF in
metastatic melanoma. J Clin Oncol 2011;29: 1239–46.
115. Anforth R, Menzies A, Byth K, et al. Factors influencing the
development of cutaneous squamous cell carcinoma in
patients on BRAF inhibitor therapy. J Am Acad Dermatol
2015;72:809–15.
116. Jakob JA, Bassett RL Jr, Ng CS, et al. NRAS mutation status is
an independent prognostic factor in metastatic melanoma.
Cancer 2012;118:4014-23.
117. Rastrelli M, Pigozzo J, di Maggio A, Tosi AL, Sileni VC, Rossi
CR. Neoadjuvant treatment with dabrafenib of unresectable
localizations from occult melanoma. Melanoma Res.
2014;24: 413–4.
118. Peuvrel L, Saint-Jean M, Quéreux G, et al. Incidence and
characteristics of melanoma brain metastases developing
during treatment with vemurafenib. J Neurooncol
2014;120:147–54.
119. Long GV, Trefzer U, Davies MA, et al. Dabrafenib in patients
with Val600Glu or Val600Lys BRAF-mutant melanoma
metastatic to the brain (BREAK-MB): amulticentre, openlabel,
phase 2 trial. Lancet Oncol 2012;13:1087–95.
120. Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined
Nivolumab and Ipilimumab or Monotherapy in Untreated
Melanoma. N Engl J Med 2015;373:23–34.
121. Postow MA, Chesney J, Pavlick AC, et al. Nivolumab and
ipilimumab versus ipilimumab in untreated melanoma. N
Engl J Med 2015;372: 2006–17.
122. Margolin K, Ernstoff MS, Hamid O, et al. Ipilimumab in
patients with melanoma and brain metastases: an open-
label, phase 2 trial. Lancet Oncol 2012;13:459–465.
123. Queirolo P, Spagnolo F, Ascierto PA, et al. Efficacy and safety of
ipilimumab in patients with advanced melanoma and brain
metastases. J Neurooncol 2014;118: 109–16.
124. Sandock, D., Seftel AD, Resnick MI. A new protocol for the
followup of renal cell carcinoma based on pathological stage.
J Urol 1995;154:28–31.
125. Levy DA, Slaton JW, Swanson DA, Dinney CP. Stage specific
guidelines for surveillance after radical nephrectomy for local
renal cell carcinoma. J Urol 1998;159:1163–7.
126. Ljungberg B, Alamdari FI, Rasmuson T, Roos G. Follow-up
guidelines for nonmetastatic renal cell carcinoma based on
the occurrence of metastases after radical nephrectomy. BJU
Int 1999;84:405–11.
127. Sheehan JP, Sun MH, Kondziolka D, Flickinger J, Lunsford LD.
Radiosurgery in patients with renal cell carcinoma metastasis
to the brain: long-term outcomes and prognostic factors
influencing survival and local tumor control. J Neurosurg
2003;98:342–9.
128. Vogl UM, Bojic M, Lamm W, et al. Extracerebral metastases
determine the outcome of patients with brain metastases
from renal cell carcinoma. BMC Cancer 2010;10:480.
129. Nieder C, Spanne O, Nordøy T, Dalhaug A. Treatment of brain
metastases from renal cell cancer. Urol Oncol 2011;29:
405–10.
130. Bennani O, Derrey S, Langlois O, et al. Brain metastasis from
renal cell carcinoma. Neurochirurgie. 2014;60:12–6.
131. Massard C, Zonierek J, Gross-Goupil M, Fizazi K, Szczylik
C, Escudier B. Incidence of brain metastases in renal cell
carcinoma treated with sorafenib. Ann Oncol 2010;21:1027–
31.
132. Dudek AZ, Raza A, Chi M, et al. Brain metastases from renal
cell carcinoma in the era of tyrosine kinase inhibitors. Clin
Genitourin Cancer 2013; 11: 155–60.
133. Verma J, Jonasch E, Allen P, Tannir N, Mahajan A. Impact of
tyrosine kinase inhibitors on the incidence of brain metastasis
in metastatic renal cell carcinoma. Cancer 2011;117:4958–
65.
134. Verma J, Jonasch E, Allen PK, et al. The impact of tyrosine
kinase inhibitors on the multimodality treatment of brain
metastases from renal cell carcinoma. Am J Clin Oncol
2013;36:620–4.
135. Gore ME, Hariharan S, Porta C, et al. et al. Sunitinib in
metastatic renal cell carcinoma patients with brain
metastases. Cancer 2011;117:501–9.
136. Gore, M.E., Szczylik, C., Porta, C., Bracarda, S., Bjarnason, G.A.,
Oudard, S., Lee, SH. Haanen, J, Castellano D, Vrdoljak E., et al.
Final results from the large sunitinib global expanded-access
trial in metastatic renal cell carcinoma. Br. J. Cancer 2015;
113; 12–19.
137. Vickers MM, Al-Harbi H, Choueiri TK, et al. Prognostic factors of
survival for patients with metastatic renal cell carcinoma with
brain metastases treated with targeted therapy: results from
the international metastatic renal cell carcinoma database
consortium. Clin Genitourin. Cancer 2013;11:311–5.
138. Kothari G, Foroudi, F, Gill S, Corcoran NM, Siva S. Outcomes
of stereotactic radiotherapy for cranial and extracranial
metastatic renal cell carcinoma: a systematic review. Acta
Oncol 2015;54:148–57.
139. Eichler AF, Chung E, Kodack DP, Loeffler JS, Fukumura D,
Jain RK. The biology of brain metastases translation to new
therapies. Nat Rev Clin Oncol 2011;8:344-56.
140. Gow CH, Chang YL, Hsu YC, et al. Comparison of epidermal
growth factor receptor mutations between primary and
corresponding metastatic tumors in tyrosine kinase inhibitor
naive non-small-cell lung cancer. Ann Oncol 2009;20:696–
702.
[METÁSTASIS CEREBRALES: UNA MIRADA BIOLÓGICA Y CLÍNICA - Dr. Manuel Álvarez y cols.]